孟鲁司特钠治疗儿童咳嗽变异性哮喘效果的临床观察

Clinical observation on montelukast in the treatment of children with cough variant asthma

目的观察孟鲁司特钠对儿童咳嗽变异性哮喘(CVA)患者血清白介素-13(IL-13)、Ig E、及全血嗜酸性粒细胞计数(EOS)水平的影响。方法 100例CVA患儿,分为对照组和观察组各50例。对照组采用常规基础治疗,观察组在对照组常规基础治疗上加服孟鲁司特钠,药物干预共进行8周,观察治疗前后血清IL-13、Ig E及外周血EOS表达水平变化及评价临床治疗疗效。结果治疗前两组患者IL-13、Ig E、EOS比较,差异无统计学意义(P>0.05)。治疗8周后,观察组IL-13、Ig E、EOS比对照组明显下降(P<0.05);观察组总有效率为70.0%,对照组总有效率为36.0%,对照组总有效率明显高于对照组(χ2=11.602,P<0.05)。结论孟鲁司特钠治疗儿童CVA疗效显著、不良反应较少,明显改善哮喘、咳嗽等临床症状。

Objective To observe the effect of montelukast on the change of serum IL-13, IgE and blood eosinophil count in children with cough variant asthma. Methods 100 children with CVA were randomly divided into the control group （50 cases）, which were given conventional therapy, and the study group （50 cases）, which were given montelukast on the basis of the control group. The clinical efficacy and the changes of serum IL-13, IgE and blood eosinophil count were observed and compared. Results There was no significant difference in IL-13, IgE and EOS between the two groups before treatment （P〉0. 05）. The expression of IL-13, IgE and EOS decreased more significantly in the study group than in the control group 8 weeks after the treatment （P〈0. 05）. The clinical efficacy in the study group were better than that in the control group （χ^2 =5. 955, P〈0. 05）. Conclusion Montelukast could significantly improve the clinical symptoms such as asthma and cough, with less adverse reactions in the treat-ment of children with CVA.